Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Anaphylaxis School Medications topic
No spam. Unsubscribe anytime.
Assembly committee clears bill allowing schools to stock new FDA‑approved epinephrine delivery systems
Summary
AB 228 (Zachary FAST Act) passed the Assembly Education Committee to Appropriations; the bill clarifies that schools may carry any federally approved epinephrine delivery device, including non‑injector options, without mandating stocking.
Assemblymember Sanchez introduced AB 228, the Zachary FAST Act, to update California law so school districts may stock federally approved epinephrine delivery systems beyond the traditional auto‑injector. The author said the measure is not a mandate but clarifies schools’ authority to maintain newer FDA‑approved devices, such as needleless nasal sprays, as they become available.
Twelve‑year‑old Zachary Munoz testified in support and described his own experience with anaphylaxis and traumatic memories of early epinephrine injections; he and his family urged passage so schools could choose less traumatic delivery options for students. Support also came from county offices of education, school nurses, PTA, and school boards.
No opposition was recorded during the hearing. Committee members praised the bill’s future‑proof language — several members called the bill “future proof” because it would allow schools to stock new delivery devices without returning to the Legislature each time technology changes. The committee voted to pass AB 228 to Appropriations (recorded roll call shows the motion passed and the bill was reported out of committee).
